IMR Press / FBL / Volume 22 / Issue 8 / DOI: 10.2741/4547

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with Frontiers in Bioscience.


Dynamic monitoring of monocyte HLA-DR expression for the diagnosis, prognosis, and prediction of sepsis

Show Less
1 Emergency Department, Shanghai Tenth People’s Hospital, School of Medicine, Tongji University, No 301, Mid Yangchang Road, Shanghai, China
Front. Biosci. (Landmark Ed) 2017, 22(8), 1344–1354;
Published: 1 March 2017
(This article belongs to the Special Issue Targeting myeloid differentiation 2 for treatment of sepsis)

Sepsis, an under-recognized health problem, is a major cause of death. More than 750,000 individuals develop sepsis annually, of whom 215,000 die of the disease. Clinical and experimental evidence indicates that patients with sepsis present with rapid impairment of immune function; biomarkers are therefore needed to enable early detection of this condition. Reduced monocyte human leukocyte antigen-DR (HLA-DR) expression, which is measured by flow cytometry, is currently the most popular biomarker for sepsis detection. In addition, the determination of HLA-DR expression provides valuable information in terms of predicting mortality and risk of secondary infections. HLA-DR levels have been shown to be inversely correlated with the severity of sepsis and immune dysfunction. In this review, we provide an overview of the association between sepsis and HLA-DR expression in terms of the predictive value of the latter in sepsis.

Human Leukocyte Antigen DR
Back to top